AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33430841 — intervention group
Group type: EXPERIMENTAL
Intervention: KalobaTUSS® syrup
Number of subjects: 106
Study 33430841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 34647174 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Tree (DT) model
Number of subjects: 600
Study 34647174 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted model (DT model) for radiologists
Number of subjects: 600
Study 36148830 — intervention group
Group type: EXPERIMENTAL
Intervention: 4L single dose polyethylene glycol (PEG) given in the evening before
Number of subjects: 641
Study 36148830 — intervention group
Group type: EXPERIMENTAL
Intervention: 4L split-dose PEG
Number of subjects: 641
Study 36148830 — intervention group
Group type: EXPERIMENTAL
Intervention: 2L split-dose PEG (+ bisacodyl 15 mg)
Number of subjects: 641
Study 36148830 — intervention group
Group type: EXPERIMENTAL
Intervention: 2L single dose PEG (+ bisacodyl 15 mg) in the morning
Number of subjects: 641
Study 36148830 — intervention group
Group type: EXPERIMENTAL
Intervention: Traveling more than an hour
Number of subjects: 641
Study 32068975 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month intervention consisting of 2 hours of physical exercise, cognitive training, and classroom study or rest once weekly
Number of subjects: 141
Study 32068975 — intervention group
Group type: COMPARATOR
Intervention: OBS-INT group during the observation period
Number of subjects: 141
Study 34855513 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level mask distribution and promotion (cloth versus surgical masks)
Number of subjects: 342183
Study 34855513 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level mask distribution and promotion
Number of subjects: 342183
Study 34855513 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical masks distributed with promotion
Number of subjects: 342183
Study 33185651 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher West African ancestry
Number of subjects: 2466
Study 33185651 — intervention group
Group type: COMPARATOR
Intervention: Intensive treatment arm
Number of subjects: 2466
Study 33185651 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment arm
Number of subjects: 2466
Study 35768804 — intervention group
Group type: EXPERIMENTAL
Intervention: High ATIRE risk score
Number of subjects: 228
Study 35768804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on ATIRE
Number of subjects: 228
Study 35768804 — intervention group
Group type: EXPERIMENTAL
Intervention: Editing of ATIRE sites
Number of subjects: 228
Study 35657960 — intervention group
Group type: EXPERIMENTAL
Intervention: Valgus knee brace (Össur Unloader One©) worn for 8 weeks
Number of subjects: 30
Study 33057976 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits (2 during pregnancy, 1 postpartum) promoting couple HIV testing and counseling (CHTC) and HIV prevention
Number of subjects: 105
Study 33057976 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 105
Study 33446133 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive nomogram based on multivariate logistic regression analysis
Number of subjects: 207
Study 33446133 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive nomogram
Number of subjects: 207
Study 34837758 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Acceptance and Commitment Therapy (G‐ACT)
Number of subjects: 104
Study 34837758 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 104
Study 32503649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 68
Study 32503649 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 68
Study 35764983 — intervention group
Group type: EXPERIMENTAL
Intervention: ENGAGE intervention
Number of subjects: 96
Study 35764983 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 96
Study 34075778 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level tragus stimulation (LLTS)
Number of subjects: 28
Study 34075778 — intervention group
Group type: COMPARATOR
Intervention: Sham (earlobe stimulation)
Number of subjects: 28
Study 32712966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (HC)
Number of subjects: 93
Study 34587830 — intervention group
Group type: EXPERIMENTAL
Intervention: Active RPSS
Number of subjects: 0
Study 34587830 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study 35537858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 20 mg/kg/d, b.i.d. for 4 weeks
Number of subjects: 0
Study 35537858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35537858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 0
Study 33160781 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary reverse mapping - selective axillary dissection (ARM-SAD)
Number of subjects: 100
Study 33160781 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 100
Study 32928870 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 993
Study 35724828 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg/day) and Zinc (15 mg/day)
Number of subjects: 0
Study 35724828 — intervention group
Group type: COMPARATOR
Intervention: Single-dose treatment with Doxycycline
Number of subjects: 0
Study 35724828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32130851 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer examiner first, then examinee
Number of subjects: 42
Study 32130851 — intervention group
Group type: COMPARATOR
Intervention: Control group - tested at a station first, then participated as a peer examiner
Number of subjects: 42
Study 33760280 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenan
Number of subjects: 14
Study 33760280 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 14
Study 35288227 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation plus adjuvant systemic therapy
Number of subjects: 3083
Study 35288227 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant systemic therapy alone
Number of subjects: 3083
Study 33673616 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin rinse solution
Number of subjects: 0
Study 33673616 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse solution
Number of subjects: 0
Study 33673616 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin in drinking water
Number of subjects: 0
Study 33673616 — intervention group
Group type: COMPARATOR
Intervention: Placebo in drinking water
Number of subjects: 0
Study 36202899 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model based on three necroptosis-related mRNAs (CXCL8, CLEC9A, TAB2)
Number of subjects: 291
Study 36202899 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 291
Study 36202899 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 291
Study 36202899 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor immune dysfunction and exclusion scores, M6A-related genes, stem cell correlation, and Tumor mutational burden data
Number of subjects: 291
Study 33546733 — intervention group
Group type: EXPERIMENTAL
Intervention: AANmDOF robotic training (combination of training in LOPES‐II and conventional gait training, 30 min, 3–5 times a week for 6 weeks)
Number of subjects: 34
Study 33546733 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training (30 min, 3–5 times a week for 6 weeks)
Number of subjects: 34
Study 32182774 — intervention group
Group type: EXPERIMENTAL
Intervention: ADORA2A rs2298383 TT mutated genotype in MCS patients
Number of subjects: 279
Study 32182774 — intervention group
Group type: COMPARATOR
Intervention: ADORA2A rs2298383 CT genotype in controls
Number of subjects: 279
Study 32182774 — intervention group
Group type: EXPERIMENTAL
Intervention: TT MCS patients
Number of subjects: 279
Study 36078940 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.4 MHz Radiofrequency (RF) therapy
Number of subjects: 118
Study 36078940 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US) therapy
Number of subjects: 118
Study 33356519 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week over-ground robotic-assisted gait training program (n=16)
Number of subjects: 34
Study 33356519 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 34
Study 37079158 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake estimated from 24‐h urinary iodine excretion (UIE)
Number of subjects: 103
Study 37079158 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake estimated from 24‐h dietary recall
Number of subjects: 103
Study 37079158 — intervention group
Group type: EXPERIMENTAL
Intervention: Household salt iodine concentration
Number of subjects: 103
Study 37079158 — intervention group
Group type: EXPERIMENTAL
Intervention: Contribution of discretionary salt to daily iodine intake
Number of subjects: 103
Study 37079158 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between iodine intake from 24‐h UIE and 24‐h dietary recall
Number of subjects: 103
Study 34229267 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed oil intravenous lipid emulsion (MO ILE)
Number of subjects: 120
Study 34229267 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil intravenous lipid emulsion (SO ILE)
Number of subjects: 120
Study 35411669 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib 10 mg
Number of subjects: 0
Study 35411669 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib 25 mg
Number of subjects: 0
Study 35411669 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib 40 mg
Number of subjects: 0
Study 35411669 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib 40 mg (with food)
Number of subjects: 0
Study 35411669 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib 40 mg (without food)
Number of subjects: 0
Study 35411669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33258356 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation (SM)
Number of subjects: 55
Study 32979249 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared room occupancy (group A)
Number of subjects: 666
Study 32979249 — intervention group
Group type: COMPARATOR
Intervention: Single room occupancy (group B)
Number of subjects: 666
Study 33066763 — intervention group
Group type: COMPARATOR
Intervention: Urban slums
Number of subjects: 3671
Study 33066763 — intervention group
Group type: COMPARATOR
Intervention: Rural areas
Number of subjects: 3671
Study 34579199 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted procedure with structured information and three text message reminders sent every two weeks
Number of subjects: 1475
Study 34579199 — intervention group
Group type: COMPARATOR
Intervention: Nonstructured information only (control)
Number of subjects: 1475
Study 33832949 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg once daily from day 1 to 14 every 3 weeks)
Number of subjects: 91
Study 33832949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 33832949 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 91
Study 34048944 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical scribes deployed in emergency departments and specialty clinics
Number of subjects: 48
Study 34048944 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (sites not randomized to intervention)
Number of subjects: 48
Study 32933755 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity troponin T (hs‐cTnT)
Number of subjects: 578
Study 32933755 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct size (IS) assessed with CMR
Number of subjects: 578
Study 32933755 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF) assessed with CMR
Number of subjects: 578
Study 32933755 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-discharge TTE-assessed LVEF
Number of subjects: 578
Study 32933755 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine kinase-MB (CKMB)
Number of subjects: 578
Study 32933755 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE score
Number of subjects: 578
Study 32933755 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI score
Number of subjects: 578
Study 32933755 — intervention group
Group type: EXPERIMENTAL
Intervention: hs‐cTnT peak value <3,500 ng/L
Number of subjects: 578
Study 34995805 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (cholecystectomy performed 7 days after MABP)
Number of subjects: 198
Study 34995805 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery (cholecystectomy performed 4 weeks after MABP)
Number of subjects: 198
Study 34995805 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 198
Study 34995805 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery
Number of subjects: 198
Study 33243761 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic psychological interventions (including signposting, guided self-help, referral to paediatric psychology service)
Number of subjects: 186
Study 32620213 — intervention group
Group type: EXPERIMENTAL
Intervention: ddMVAC plus durvalumab alone or with tremelimumab
Number of subjects: 120
Study 32620213 — intervention group
Group type: COMPARATOR
Intervention: ddMVAC
Number of subjects: 120
Study 35170786 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led smartphone-based self-management programme (NSSMP) for 6 months
Number of subjects: 114
Study 35170786 — intervention group
Group type: COMPARATOR
Intervention: Nurse-led diabetic service (NDS)
Number of subjects: 114
Study 35170786 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led smartphone-based self-management programme (NSSMP)
Number of subjects: 114
Study 34318438 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled oral regimen of ibuprofen plus acetaminophen (alternating every 3 hours or concurrent every 6 hours for 5 days)
Number of subjects: 0
Study 34318438 — intervention group
Group type: EXPERIMENTAL
Intervention: HTX-011 (300 mg bupivacaine/9 mg meloxicam)
Number of subjects: 0
Study 34318438 — intervention group
Group type: EXPERIMENTAL
Intervention: HTX-011 with ibuprofen/acetaminophen
Number of subjects: 0
Study 33576284 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity prescription (PAP)
Number of subjects: 121
Study 33576284 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic information about postoperative PA)
Number of subjects: 121
Study 33752581 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-clinician dyads with less similar perceptions of the client's subjective social status (SSS)
Number of subjects: 312
Study 33752581 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians' correct perception of their clients' social status
Number of subjects: 312
Study 34980096 — intervention group
Group type: EXPERIMENTAL
Intervention: 55% cocoa chocolate (IG1, n = 16)
Number of subjects: 46
Study 34980096 — intervention group
Group type: EXPERIMENTAL
Intervention: White chocolate (IG2, n = 15)
Number of subjects: 46
Study 34980096 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 15)
Number of subjects: 46
Study 32828187 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement and community health worker-led mobile health-supported early detection, initial treatment, and hospital referral of women with hypertension.
Number of subjects: 69330
Study 32828187 — intervention group
Group type: COMPARATOR
Intervention: Control group continued local standard of care.
Number of subjects: 69330
Study 33433847 — intervention group
Group type: EXPERIMENTAL
Intervention: Danhong Injection (40 mL twice a day for a week)
Number of subjects: 90
Study 33433847 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins intensive group (atorvastatin 80 mg once, then 40 mg daily for 1 week)
Number of subjects: 90
Study 33433847 — intervention group
Group type: COMPARATOR
Intervention: Control group (atorvastatin 10–20 mg daily for 1 week)
Number of subjects: 90
Study 34871590 — intervention group
Group type: EXPERIMENTAL
Intervention: FOODcamp intervention
Number of subjects: 640
Study 33462619 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted 1-SD increase of serum IGF-1 levels
Number of subjects: 358072
Study 33462619 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted 1-SD increase of serum IGF-1 levels after adjustment for eBMD
Number of subjects: 358072
Study 32831169 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Initiation of ART for All (EAAA)
Number of subjects: 3019
Study 35939965 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation + advice only (PE)
Number of subjects: 200
Study 35939965 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation + simplified motor in‐sensu AAT instruction (AAT0)
Number of subjects: 200
Study 35939965 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched original imaginal retraining technique (AAT+)
Number of subjects: 200
Study 35939965 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 200
Study 34496940 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMPLS-based model for predicting hospital mortality
Number of subjects: 250
Study 34496940 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and comorbidity predictors and blood biochemical markers
Number of subjects: 250
Study 34496940 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustering analysis
Number of subjects: 250
Study 33726903 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg or 30 mg once daily)
Number of subjects: 220
Study 33726903 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 220
Study 33661141 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion (0.05 μg·kg‐1·min‐1) for 30 min before spinal anesthesia
Number of subjects: 177
Study 33661141 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine bolus (0.15 mg/kg) before spinal anesthesia
Number of subjects: 177
Study 33661141 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 177
Study 33661141 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine bolus
Number of subjects: 177
Study 32690523 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond-enriched diet (AED) (15% energy from almonds)
Number of subjects: 134
Study 32690523 — intervention group
Group type: COMPARATOR
Intervention: Nut-free control diet (NFD) (15% energy from carbohydrate-rich snack foods)
Number of subjects: 134
Study 32690523 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond-enriched diet (AED)
Number of subjects: 134
Study 32690523 — intervention group
Group type: COMPARATOR
Intervention: Nut-free control diet (NFD)
Number of subjects: 134
Study 35398908 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 20
Study 35398908 — intervention group
Group type: COMPARATOR
Intervention: Music-only condition (sham treatment)
Number of subjects: 20
Study 33442031 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (HBPM)
Number of subjects: 501
Study 32925739 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy (TBx) alone
Number of subjects: 312
Study 32925739 — intervention group
Group type: COMPARATOR
Intervention: MRI-targeted biopsy (TBx) plus systematic biopsy (SBx)
Number of subjects: 312
Study 35395926 — intervention group
Group type: EXPERIMENTAL
Intervention: Puzzle video game training (12 hours over 4 weeks)
Number of subjects: 0
Study 35395926 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 33849942 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness fundoplication (EFTP)
Number of subjects: 70
Study 33849942 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 70
Study 32054731 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily
Number of subjects: 0
Study 32054731 — intervention group
Group type: COMPARATOR
Intervention: Acalabrutinib 200 mg once daily
Number of subjects: 0
Study 32054731 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 0
Study 36356331 — intervention group
Group type: COMPARATOR
Intervention: Individual planning condition
Number of subjects: 320
Study 36356331 — intervention group
Group type: COMPARATOR
Intervention: Dyadic planning condition
Number of subjects: 320
Study 36356331 — intervention group
Group type: COMPARATOR
Intervention: Collaborative planning condition
Number of subjects: 320
Study 34469056 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 656
Study 34469056 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 656
Study 34469056 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT subgroup (CI100 ?0.37)
Number of subjects: 656
Study 35921114 — intervention group
Group type: EXPERIMENTAL
Intervention: 195 mg transdermal cannabidiol
Number of subjects: 0
Study 35921114 — intervention group
Group type: EXPERIMENTAL
Intervention: 390 mg transdermal cannabidiol
Number of subjects: 0
Study 35921114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34967189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dissonance-based virtual program (two psycho-educative and four cognitive dissonance sessions)
Number of subjects: 0
Study 34967189 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 0
Study 34467639 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-food supplementation (daily supplementation starting before 9 gestation weeks)
Number of subjects: 640
Study 34467639 — intervention group
Group type: COMPARATOR
Intervention: Usual-food supplementation (daily supplementation starting at 20 gestation weeks)
Number of subjects: 640
Study 34467639 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal supplementation with 30-mg or 60-mg iron with 400-µg folic acid or multiple micronutrients (MM)
Number of subjects: 640
Study 34467639 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-food and MM groups
Number of subjects: 640
Study 34467639 — intervention group
Group type: EXPERIMENTAL
Intervention: STAT5b expression
Number of subjects: 640